Hartl, D M <br/><br/>
Bevacizumab-induced laryngeal necrosis.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Jan 2012 
 - 276-278 p.  digital 
<br/><br/> Publication Type: Case Reports; Letter 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdr515  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antineoplastic Agents--adverse effects<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Cisplatin--administration & dosage<br/>Clinical Trials, Phase I as Topic<br/>Deoxycytidine--administration & dosage<br/>Female<br/>Glutamates--administration & dosage<br/>Guanine--administration & dosage<br/>Humans<br/>Laryngeal Diseases--chemically induced<br/>Lung Neoplasms--drug therapy<br/>Middle Aged<br/>Necrosis--chemically induced<br/>Neoplasm Recurrence, Local--drug therapy<br/>Paclitaxel--administration & dosage<br/>Pemetrexed<br/>Tubulin Modulators--administration & dosage<br/>Gemcitabine